Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 526,652
  • Shares Outstanding, K 59,108
  • Annual Sales, $ 216,110 K
  • Annual Income, $ -220,470 K
  • EBIT $ -144 M
  • EBITDA $ -134 M
  • 60-Month Beta 0.62
  • Price/Sales 2.44
  • Price/Cash Flow N/A
  • Price/Book 1.61

Options Overview Details

View History
  • Implied Volatility 171.26% (+101.83%)
  • Historical Volatility 124.06%
  • IV Percentile 97%
  • IV Rank 47.09%
  • IV High 332.52% on 11/14/25
  • IV Low 27.75% on 09/04/25
  • Expected Move (DTE 19) 1.05 (11.73%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 1,730
  • Volume Avg (30-Day) 3,043
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 44,754
  • Open Int (30-Day) 35,197
  • Expected Range 7.86 to 9.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.53
  • Number of Estimates 2
  • High Estimate -0.49
  • Low Estimate -0.57
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -6.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.73 +55.50%
on 02/20/26
9.09 -1.98%
on 02/23/26
+0.89 (+11.10%)
since 01/27/26
3-Month
4.89 +82.21%
on 12/03/25
9.60 -7.19%
on 12/31/25
+3.61 (+68.11%)
since 11/26/25
52-Week
3.81 +133.91%
on 05/15/25
9.60 -7.19%
on 12/31/25
+4.21 (+89.57%)
since 02/27/25

Most Recent Stories

More News
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

WASHINGTON , Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami...

VNDA : 8.91 (+3.60%)
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

WASHINGTON , Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics...

VNDA : 8.91 (+3.60%)
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

WASHINGTON , Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets,...

VNDA : 8.91 (+3.60%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are...

VNDA : 8.91 (+3.60%)
Vanda: Q4 Earnings Snapshot

Vanda: Q4 Earnings Snapshot

VNDA : 8.91 (+3.60%)
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

WASHINGTON , Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December...

VNDA : 8.91 (+3.60%)
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Conference Call and Webcast to Follow

VNDA : 8.91 (+3.60%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA).  Such investors...

VNDA : 8.91 (+3.60%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are...

VNDA : 8.91 (+3.60%)
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation

New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:...

VNDA : 8.91 (+3.60%)

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 10.02
2nd Resistance Point 9.51
1st Resistance Point 9.21
Last Price 8.91
1st Support Level 8.40
2nd Support Level 7.90
3rd Support Level 7.60

See More

52-Week High 9.60
Last Price 8.91
Fibonacci 61.8% 7.39
Fibonacci 50% 6.70
Fibonacci 38.2% 6.02
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar